Morgan Stanley Maintains Equal-Weight on PTC Therapeutics, Lowers Price Target to $47
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Jeffrey Hung has maintained an Equal-Weight rating on PTC Therapeutics (NASDAQ:PTCT) and lowered the price target from $50 to $47.
July 11, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on PTC Therapeutics and lowered the price target from $50 to $47.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on PTC Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100